EXPD-101/FXS7553 not checked
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 2
- “This is a Phase 2 study of the efficacy, safety, tolerability and pharmacokinetics of two doses of EXPD-101 in participants with COPD. Study participants will be randomized to receive either study drug or placebo administered once daily for 52 weeks.”In the company’s words, NCT07684820 on ClinicalTrials.gov
Other drugs for Chronic Obstructive Pulmonary Disease (COPD)
- TQC3721Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase 3
- EnsifentrineMerck & Co. · Nuance Pharma · Phase 3
- HSK39004Haisco Pharmaceutical Group Co., Ltd. · Phase 3
- AstegolimabRoche · Phase 3
- Alpha-1 MPGrifols Therapeutics LLC · Phase 3
- JKN2401Joincare Pharmaceutical Group Industry Co., Ltd · Phase 3
Coming up1
- 30 Jun 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 30 Jun 2028 | To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026